Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118316 | 0.81 | TSHR (0.35) | TSHRKDM4EKMT2AL3MBTL1 | |
| SCHEMBL391840 | 0.78 | TSHR (0.59) | TSHRKDM4EL3MBTL1 | |
| SCHEMBL27833260 | 0.78 | TSHR (0.66) | TSHRCASP1KDM4EKMT2AOPRM1 | |
| SCHEMBL820441 | 0.75 | TSHR (0.41) | TSHR | |
| SCHEMBL28614905 | 0.73 | KDM4E (0.47) | TSHRKDM4EKMT2A | |
| SCHEMBL13195927 | 0.72 | TAAR1 (0.50) | TSHROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1911096 | 0.72 | TAAR1 (0.50) | TSHROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12846898 | 0.72 | TAAR1 (0.50) | TSHROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL816635 | 0.72 | TSHR (0.38) | TSHRKDM4E | |
| SCHEMBL3056692 | 0.71 | TSHR (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802895-B2 | Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same | CLEVELAND STATE UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2629767-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | Cleveland State University (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054417-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | CLEVELAND STATE UNIVERSITY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095092-A1 | AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME | RB1, BCR, NRAS | TSHR 493/4885CASP1 2655/4885MCHR1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.